化疗后奥希替尼治疗表皮生长因子受体突变的 III 期 NSCLC

IF 96.2 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

New England Journal of Medicine Pub Date : 2024-10-24 DOI:10.1056/nejmc2411471

引用次数: 0

摘要

致编辑Lu等人的试验（8月15日刊）1显示，奥希替尼对III期非小细胞肺癌（NSCLC）患者的无进展生存期有显著的益处，且...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

To the Editor: The trial by Lu et al. (Aug. 15 issue)1 showed a significant progression-free survival benefit with osimertinib in patients with stage III non–small-cell lung cancer (NSCLC) with an ...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

New England Journal of Medicine 医学-医学：内科

CiteScore

145.40

自引率

0.60%

发文量

1839

审稿时长

1 months

期刊介绍： The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.